About 100 reports

Cancer is the second-leading cause of death in the US, and accounts for nearly one in every four deaths.

  • Biopsy
  • Cancer
  • Biocept, Inc.
  • Biodesix Inc.
  • Roche Group
  • TABLE OF CONTENTS
  • EXECUTIVE SUMMARY

‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also...

  • Breast Cancer
  • Cancer
  • World
  • Market Size
  • Roche Group
  • Europe Cervical Cancer Diagnostics Market
  • Global Cervical Cancer Diagnostics Market- Product Benchmarking

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of global cervical cancer diagnostics market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies),...

  • Cancer
  • Cervical Cancer
  • Diagnostics
  • Healthcare
  • Roche Group
  • EMERGENCE OF TARGETED AND COMBINATION THERAPIES FOR BREAST CANCER
  • HUGE MARKET POTENTIAL FOR BREAST CANCER MABS OWING TO PRODUCT APPROVALS

About Breast Cancer mAbs Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates...

  • Cancer
  • United States
  • World
  • Market Size
  • Roche Group
  • 2.4 ROCHE WILL CONTINUE TO MONOPOLIZE THE HER2-POSITIVE BREAST CANCER MARKET,
  • KEY COMPANIES IN THE HER2-POSITIVE BREAST CANCER MARKET IN THE 8MM, 2015-2025

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established...

  • Breast Cancer
  • Cancer
  • Therapy
  • World
  • Roche Group
  • Geographical segmentation
  • Market drivers

You can easily book an appointment with one online.

  • Cancer
  • Cancer Diagnostic
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Roche Group
  • Breast Cancer Therapeutics Market, Competitor Matrix for HER2-Positive Breast Cancer Marketed and Pipeline Products,
  • Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2018

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence Summary Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production, called lobules, and the ducts...

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Roche Group
  • Executive Summary
  • PRODUCT PROFILE - AVASTIN

GENES CANCER; ##(##): ##- ##.

  • Cancer
  • Colorectal Cancer
  • Hospital
  • Therapy
  • Roche Group
  • HER2-NEGATIVE BREAST CANCER: KEY METRICS IN THE EIGHT MAJOR PHARMACEUTICAL MARKETS
  • KEY COMPANIES IN THE DISEASE HER2- BREAST CANCER MARKET IN THE 8MM, 2015

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer...

  • Cancer
  • East Asia
  • Forecast
  • Market Size
  • Roche Group

With the number of Canadians aged ## and older expected to grow by 2030 -- moving from one in eight now, to one in four -- the face of cancer will change.

  • Cancer
  • Cancer Diagnostic
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Roche Group
  • 6.9.3 MARKET SIZE
  • 9 Appendix

Breast Cancer; ##(##): ##-## Juric D, et al. (2015).

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Roche Group
  • 9.1.4 PHASE I
  • 8.2.4 KEY CO-DEVELOPMENT DEALS

BMC Cancer; ##(##); ##-## Lubin JH, et al. (2004).

  • Cancer
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Roche Group
  • EARLY-STAGE CLINICAL DEVELOPMENT IN NSCLC
  • TECENTRIQ SWOT ANALYSIS, 2016

INTERNATIONAL JOURNAL OF CANCER; ##(##): ##-##.

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Roche Group
  • UROLOGICAL CANCER, GLOBAL, KEY MARKETED PRODUCTS AND APPROVED INDICATIONS, 2015
  • C) TREATED POPULATION

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics Summary Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered...

  • Cancer
  • Therapy
  • Urology
  • Pfizer Inc.
  • Roche Group
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, CLUSTER BY GROWTH AND
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, PROPORTION OF TOTAL

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market Summary Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological...

  • Cancer
  • Leukemia
  • World
  • Idera Pharmaceuticals, Inc.
  • Roche Group
  • Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
  • Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it...

  • Cancer
  • Gastric Cancer
  • Monoclonal Antibody
  • Therapy
  • Roche Group
  • Promising Drugs in Development for CRC

Colorectal Cancer: Competitive Landscape to 2026 Report Code: GDHC##CL Published: April 2018 Healthcare TABLE OF CONTENTS ##.

  • Cancer
  • China
  • United States
  • Market Competition
  • Roche Group
  • Market Drivers / Barriers
  • Novel Therapies in Breast Cancer Treatment

This report, the World Market for Cancer Therapeutics presents a detailed picture of the market for cancer drugs, with a focus on novel therapies. The market analysis in this report includes analysis of products avaiable for each cancer type (Breast Cancer, Lung Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Colon Cancer and Other types)...

  • Cancer
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • Roche Group
  • EXPECTED KEY UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE
  • KOL INSIGHT ON THE UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE (APRIL 2017-FEBRUARY 2018)

Bladder Cancer: Dynamic Market Forecast to 2026 Summary Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including...

  • Cancer
  • Vaccine
  • Market Size
  • Eli Lilly & Co.
  • Roche Group
  • CANCER STEM CELLS: LIST OF MOLECULES PROFILED (MARKETED AND PHASE III)
  • CANCER STEM CELL THERAPIES: EXPECTED LAUNCH YEARS OF ADVANCED STAGE DRUG CANDIDATES

INTRODUCTION Cancer stem cells (CSCs) are known to be rare, immortal cells within a tumor that can both self-renew and differentiate into several cell types that form the tumor mass. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation...

  • Cancer
  • Pharmaceutical
  • Therapy
  • Novartis AG
  • Roche Group
  • C) Treatment population
  • 2.3 PATHOPHYSIOLOGY AND ETIOLOGY

Cancer Discovery; ##(##): ##-## Hanahan D and Weinberg RA (2011).

  • Cancer
  • World
  • Market Size
  • Idera Pharmaceuticals, Inc.
  • Roche Group
  • Scope of the report
  • Market size and forecast

Cancer Testing Market in the US 2015-2019 Covering: Market size and forecast of the cancer testing market in the US and segmentation by technique, including genetic testing and conventional testing. The report discusses the major drivers influencing market growth and the challenges faced by the vendors and the market as a whole. The top...

  • Cancer
  • United States
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Roche Group
  • KEY UPDATES IN ALKM+ NSCLC
  • Abbreviations

Event ##: Market Dynamics Shift in Frontline NSCLC ## ##.

  • Cancer
  • Lung Cancer
  • Therapy
  • AstraZeneca PLC
  • Roche Group

Gastric cancer

4385 5000 3900
  • Marketed Drugs: Gastric Cancer
  • Pipeline: Gastric Cancer

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market? - How will pipeline immunotherapies...

  • Cancer
  • Chemotherapy
  • Gastric Cancer
  • Therapy
  • Roche Group
  • 11.11.5 BUSINESS STRATEGY
  • BYPRODUCTS

Metastatic Breast Cancer Pertuzumab& Trastuzumab Phase ## Phase ## Phase ## Company / University Condition Product / Intervention Description Phase Peking University & Cell Biotech Co.

  • Biopsy
  • Cancer
  • Diagnostics
  • Healthcare
  • Roche Group
  • 9.3 BIBLIOGRAPHY
  • 5.13 MARGETUXIMAB - MACROGENICS

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence Summary Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making...

  • Breast Cancer
  • Cancer
  • Therapy
  • World
  • Roche Group
  • 5.2 References
  • 3.1 Early-Stage Adjuvant Therapy

Typically, grade one cancers are well-differentiated and proliferate slowly, while grade four cancers are relatively undifferentiated, which enables them to proliferate rapidly.

  • Cancer
  • Colorectal Cancer
  • Therapy
  • United States
  • Roche Group
  • 2.3.5 NON-SMALL CELL LUNG CANCER
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Roche Group
  • 6.1 GLOBAL PD-1 AND PD-L1 INHIBITORS MARKET: COMPETITIVE LANDSCAPE
  • 7.3.3 Business Strategy

Scope of the Report The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1...

  • Cancer
  • Hepatitis
  • Lung Cancer
  • Therapy
  • Roche Group
  • 9.3 BIBLIOGRAPHY
  • 2.7 PROGNOSIS AND DISEASE STAGING

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence Summary Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the...

  • Cancer
  • Therapy
  • World
  • Market Size
  • Roche Group